Bill Summary
S. 3314 directs the Secretary of Veterans Affairs to expand an existing Veterans Health Administration informed-consent directive, which currently applies to long-term opioid therapy, so that it also covers five additional classes of medications: antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics. The bill, titled the “Written Informed Consent Act,” requires that veterans receive clear, written information about the risks, benefits, and alternatives before starting these powerful drugs, and that they provide explicit informed consent rather than being placed on such medications by default. The goal is to strengthen transparency and patient autonomy within VA healthcare when prescribing medications that can significantly affect mental health, cognition, behavior, and dependency risk.
S. 3314 directs the Secretary of Veterans Affairs to expand an existing Veterans Health Administration informed-consent directive, which currently applies to long-term opioid therapy, so that it also covers five additional classes of medications: antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics. The bill, titled the “Written Informed Consent Act,” requires that veterans receive clear, written information about the risks, benefits, and alternatives before starting these powerful drugs, and that they provide explicit informed consent rather than being placed on such medications by default. The goal is to strengthen transparency and patient autonomy within VA healthcare when prescribing medications that can significantly affect mental health, cognition, behavior, and dependency risk.
Why It Matters to the Make America Healthy Again Movement
The MAHA Movement supports this bill because it pushes the VA system toward real informed consent before veterans are started on high-risk psychiatric and pain medications that can have profound, long-term effects. By requiring written informed consent across major drug classes—not just opioids—S. 3314 aligns with MAHA’s emphasis on transparency, patient autonomy, and caution around powerful pharmaceutical interventions, especially for vulnerable populations like veterans.